Overview

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Status:
Not yet recruiting

Trial end date:
2023-01-09

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 1 study is to evaluate the effect of various degrees of renal impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155. The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with renal impairment

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Pharmaceutical Research Associates